Hyperprolactinemia and galactorrhea induced by serotonin and norepinephrine reuptake inhibiting antidepressants.
Ashton
Adam Keller
AK
Longdon
Marlene C
MC
D018759:Adrenergic Uptake Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D000328:Adult; D003511:Cyclohexanols / Q000009:adverse effects* / Q000627:therapeutic use; D000068736:Duloxetine Hydrochloride; D019263:Dysthymic Disorder / Q000188:drug therapy*; D005260:Female; D005687:Galactorrhea / Q000139:chemically induced*; D006801:Humans; D006966:Hyperprolactinemia / Q000139:chemically induced*; D009638:Norepinephrine / Q000037:antagonists & inhibitors; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D013876:Thiophenes / Q000009:adverse effects* / Q000627:therapeutic use; D000069470:Venlafaxine Hydrochloride
D018759:Adrenergic Uptake Inhibitors; D003511:Cyclohexanols; D000068736:Duloxetine Hydrochloride; D009638:Norepinephrine; D017367:Selective Serotonin Reuptake Inhibitors; D013876:Thiophenes; D000069470:Venlafaxine Hydrochloride